Health Condition 1: C00-D49- Neoplasms
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Elephas Biosciences Corporation
Eligibility
Inclusion criteria
Inclusion criteria: 1. Able and willing to provide informed consent for participation 2. Age more than 18 years at time of consent. 3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.
Exclusion criteria
Exclusion criteria: 1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment. 2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients. 3. Pregnant person(s).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collect human tumor specimens to research mechanisms of tumor cutting, imaging, and ex vivo immunotherapy treatment response, while maintaining cell stability in a live tumor microenvironment to train AI and ML algorithms.Timepoint: Screening (D-90 to D0), Baseline (D0-D30), Followups at 3m, 6m, 12m,24m, & 36m post biopsy. | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India, United States of America
Contacts
Public ContactDr Ghanashyam Biswas
SPARSH - American Oncology Institute (AOI) Odisha
Outcome results
None listed